(Q26851894)

language of work or name

1 reference

February 2015

1 reference

American Journal of Hematology

published in

1 reference

volume

90

1 reference

issue

2

1 reference

page(s)

162-73

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

cites work

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

21 January 2018

1 reference

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

Presence of calreticulin mutations in JAK2-negative polycythemia vera.

21 January 2018

1 reference

Somatic mutations of calreticulin in myeloproliferative neoplasms

21 January 2018

1 reference

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

21 January 2018

1 reference

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

21 January 2018

1 reference

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

21 January 2018

1 reference

Two rare MPL gene mutations in patients with essential thrombocythemia.

21 January 2018

1 reference

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia

21 January 2018

1 reference

Germline JAK2 mutation in a family with hereditary thrombocytosis.

21 January 2018

1 reference

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

21 January 2018

1 reference

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

21 January 2018

1 reference

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

21 January 2018

1 reference

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

21 January 2018

1 reference

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients

21 January 2018

1 reference

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

21 January 2018

1 reference

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

21 January 2018

1 reference

Cardiovascular events and intensity of treatment in polycythemia vera

21 January 2018

1 reference

Personalized management of essential thrombocythemia-application of recent evidence to clinical practice

21 January 2018

1 reference

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

21 January 2018

1 reference

Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia

21 January 2018

1 reference

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

21 January 2018

1 reference

Calreticulin mutations and long-term survival in essential thrombocythemia

21 January 2018

1 reference

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

21 January 2018

1 reference

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

21 January 2018

1 reference

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

21 January 2018

1 reference

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

21 January 2018

1 reference

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

21 January 2018

1 reference

Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations

21 January 2018

1 reference

Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies

21 January 2018

1 reference

Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies

21 January 2018

1 reference

A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs.

21 January 2018

1 reference

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

21 January 2018

1 reference

Pruritus in polycythaemia vera: prevalence, laboratory correlates and management

21 January 2018

1 reference

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

21 January 2018

1 reference

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

21 January 2018

1 reference

Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.

21 January 2018

1 reference

Pregnancy in essential thrombocythaemia: experience with 40 pregnancies

21 January 2018

1 reference

A single institutional experience with 43 pregnancies in essential thrombocythemia

21 January 2018

1 reference

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

21 January 2018

1 reference

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe

21 January 2018

1 reference

Thrombocythaemia and pregnancy

21 January 2018

1 reference

Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus

21 January 2018

1 reference

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera.

21 January 2018

1 reference

The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation

21 January 2018

1 reference

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial

21 January 2018

1 reference

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

21 January 2018

1 reference

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

21 January 2018

1 reference

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis

21 January 2018

1 reference

A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)

21 January 2018

1 reference

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

21 January 2018

1 reference

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution

21 January 2018

1 reference

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

21 January 2018

1 reference

Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre

21 January 2018

1 reference

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

21 January 2018

1 reference

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 January 2018

1 reference

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

21 January 2018

1 reference

JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

21 January 2018

1 reference

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

21 January 2018

1 reference

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count

21 January 2018

1 reference

7 January 2021

Co-present rheumatoid arthritis and gout successfully treated with abatacept

1 reference

7 January 2021

DNMT3A mutations in myeloproliferative neoplasms

1 reference

7 January 2021

Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991)

1 reference

7 January 2021

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

7 January 2021

Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia

1 reference

7 January 2021

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

1 reference

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

7 January 2021

Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period

1 reference

7 January 2021

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients

1 reference

7 January 2021

Complications and causes of death in polycythaemia vera

1 reference

7 January 2021

The Reticulin Content of Bone Marrow in Acute Leukaemia in Adults

1 reference

7 January 2021

Treatment of primary proliferative polycythaemia by venesection and busulphan

1 reference

7 January 2021

Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera

1 reference

7 January 2021

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

1 reference

7 January 2021

Rituximab and abatacept for rheumatoid arthritis

1 reference

7 January 2021

Mutant molecules of interest in myeloproliferative neoplasms: introduction

1 reference

7 January 2021

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

1 reference

7 January 2021

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

1 reference

7 January 2021

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

1 reference

7 January 2021

Bone marrow fibrosis and diagnosis of essential thrombocythemia

1 reference

7 January 2021

Identifiers

DOI

10.1002/AJH.23895

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25611051

1 reference

Consolidated OpenCitations Corpus – April 2017